People · Operator
Named in public records as an officer, director or promoter · active 2015–2018 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Btg Plc | — | Pharmaceuticals | Series A | $8.7M | $126.0M | 2015 |
| Senior Plc | — | Other Technology | Pre-Seed | $928K | $39.3M | 2015 |
Giles Kerr at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Giles Kerr on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gregory Barrett | 1 | 4 |
| Mark Vernon | 1 | 3 |
| Charles Berry | 1 | 2 |
| Jim O'Shea | 1 | 1 |
| Ian Much | 1 | 1 |
| Rolf Soderstrom | 1 | 1 |
| Garry Watts | 1 | 1 |
| Paul Mussenden | 1 | 1 |
| Sue Foden | 1 | 1 |
| Duncan Kennedy | 1 | 1 |
| Graham Hetherington | 1 | 1 |
| Susan Foden | 1 | 1 |
| Anne Thorburn | 1 | 1 |
| Andy Hamment | 1 | 1 |
| Andrew Bodenham | 1 | 1 |
| Celia Baxter | 1 | 1 |
| Derek Harding | 1 | 1 |
| Richard Wohanka | 1 | 1 |
| David Squires | 1 | 1 |
| Louise Makin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.